Hypertension in a pregnancy with renal anemia after recombinant human erythropoietin (rhEPO) therapy.
Management of renal anemia in pregnancy remains a major issue. We report the use of human recombinant erythropoietin (rhEPO) combined with parenteral iron sucrose in a pregnancy with chronic glomerulonephritis, progressive anemia and initially normal blood pressure. Therapy from 32 weeks gestation increased the hematocrit by 0.4% daily and the hemoglobin from 8.6 to 10.3 g/dL within 2 weeks. Despite the improvement of anemia, Cesarean section had to be performed at 34 weeks due to acute hypertension, preeclampsia and worsening renal function. Blood pressure remained elevated postpartum. Because of symptomatic postpartum anemia with a hemoglobin of 7.5 g/dL on the 5th postoperative day rhEPO in combination with parenteral iron sucrose was readministered over 3 following days. Blood pressure reached a maximum of 210/130 mm Hg 3 weeks later. Possible causes include advancing preeclampsia and renal disease, but also rhEPO (due to its intrinsic vascular effects and/or the rapid response of the hematocrit), and a combination of both.
Kashiwagi
M
M
Department of Obstetrics & Gynecology, Clinic of Obstetrics & Division of Perinatal Physiology, Frauenklinikstrasse 10, CH-8091 Zurich. maki.kashiwagi@fhk.usz.ch
Breymann
C
C
Huch
R
R
Huch
A
A
D000328:Adult; D000740:Anemia / Q000188:drug therapy*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D005921:Glomerulonephritis; D006801:Humans; D011225:Pre-Eclampsia; D011247:Pregnancy; D011644:Puerperal Disorders / Q000188:drug therapy*; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin